Subscribe To

Price Alert Latest News Economic Calendar News

RSPI / RespireRx Pharmaceuticals notes publication of paper on newest GABAkine analog which protects against seizures and lethality

RespireRx Pharmaceuticals (OTCQB:RSPI) Inc has noted the publication of a paper detailing the company's newest candidate D5-KRM-II-81, which is a so-called GABAkine - a type of medicine which enhances the inhibitory neurotransmitter in the brain. This latest asset is a structurally related analog to KRM-II-81, which, as previously reported, RespireRX's EndeavourRx business unit is advancing for the treatment of epilepsy and chronic pain. Read More

Demo Live Account See Partner Details

Content Topics

Respirerx

Pharmaceuticals

Notes

Publication

Paper

Newest

Gabakine

Analog

Protects

Against

Seizures

Lethality

Stock

RSPI

Posted: Mar 17 2022, 09:49

Author Name: Proactive Investors

RSPI News

By Proactive Investors
May 24, 2023

RespireRx Pharmaceuticals' Australia cannabis subsidiary inks LOI securing $3.1M investment

RespireRx Pharmaceuticals (OTC:RSPI) Inc subsidiary ResolutionRx Ltd entered into a binding letter of intent last week with Cantheon Capital, in whic

By Proactive Investors
April 3, 2023

RespireRx Pharmaceuticals highlights analogs of its anti-seizure treatment in scientific publications

RespireRx Pharmaceuticals (OTC:RSPI) Inc has announced the publication of four articles describing the pharmacological activity of novel structural an

By Proactive Investors
March 28, 2023

RespireRx Pharmaceuticals appoints Joseph Siegelbaum as independent director on its board

RespireRx Pharmaceuticals (OTC:RSPI) Ltd has announced the appointment of Joseph Siegelbaum to the company's board as an independent director, effect

By Proactive Investors
February 1, 2023

RespireRx Pharmaceuticals' Australian subsidiary inks loan agreements to advance R&D for sleep apnea treatment

RespireRx Pharmaceuticals (OTC:RSPI) Inc announced that its recently created Australia-based subsidiary ResolutionRx Ltd has signed a letter of intent

By Proactive Investors
January 23, 2023

RespireRx Pharmaceuticals strikes second amendment to its license agreement with the University of Illinois

RespireRx Pharmaceuticals (OTC:RSPI) Inc revealed that the company and the Board of Trustees of University of Illinois (UIL), have agreed to a second

By Proactive Investors
January 12, 2023

RespireRX Pharmaceuticals establishes ResolutionRX in Australia to advance its cannabinoid program

RespireRx Pharmaceuticals (OTC:RSPI) Inc said that as of January 11, 2023, it has established a new, currently wholly-owned, unlisted public company i

By Proactive Investors
December 5, 2022

RespireRx Pharmaceuticals joins NIH program to find non-opioid pain-relief mechanisms to combat addiction

RespireRx Pharmaceuticals (OTC:RSPI) Inc announced that it has been accepted into the National Institute of Health's (NIH) Helping to End Addiction Lo

By Proactive Investors
November 17, 2022

RespireRx Pharmaceuticals signs letter of intent with Australian CRO to study drug for treating obstructive sleep apnea

RespireRx Pharmaceuticals (OTCQB:RSPI) said it has signed a letter of intent with a bespoke clinical research organization in Australia that focuses o

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.